People with type 3 Gaucher disease have long had medicines for what the condition does to the spleen, liver and blood, and nothing approved for what it does to balance, coordination and thinking. On Nov. 18 the U.S. Food and Drug Administration approved a once-daily tablet, Infilbray (venglustat), as the first treatment for the neurological symptoms of the disease.
Genzyme Corporation, a Sanofi company, is the sponsor, and the approval came a week before the Nov. 25 target date for the FDA’s decision, a date Sanofi had disclosed when it announced priority review in May.
An FDA approval built on a 43-patient trial
The agency’s announcement says Infilbray is approved for adults and pediatric patients weighing at least 15 kilograms, about 33 pounds. It carries Orphan Drug and Priority Review designations. The agency describes type 3 as a rare, inherited condition in which the body cannot properly break down glucosphingolipids because an enzyme is deficient or malfunctioning; unlike type 1, it affects the brain and nervous system, causing problems with balance, coordination, speech, memory and thinking that can worsen over time. The supporting study was a randomized, double-blind, multicenter trial of 43 patients aged 12 and older with type 3 disease, all of whom had already received enzyme replacement therapy and reached systemic stabilization.
For 52 weeks, patients took either oral Infilbray once daily or intravenous enzyme replacement every two weeks. At week 52, those on Infilbray improved on a combined measure of two neurological assessments, ataxia (loss of muscle control and coordination) and cognitive function, compared with patients who stayed on enzyme replacement.
Acting FDA Commissioner Kyle Diamantas said: “For patients with Type 3 Gaucher disease, harmful substances build up in the brain without a way to stop them.”
Why the brain was the missing piece
Gaucher disease comes in three types, according to the National Institute of Neurological Disorders and Stroke. Type 3 is the chronic neuronopathic form, can begin in childhood or adulthood, and brings an enlarged liver and spleen plus neurological symptoms such as seizures and cognitive decline that are milder than in type 2 and progress slowly. The institute’s page says there is no effective treatment for severe brain damage in types 2 and 3.
The reason lies in how existing drugs travel. A review of Gaucher therapies states that the administered enzymes do not cross the blood-brain barrier, so neurologic manifestations of types 2 and 3 do not respond to enzyme replacement. Miglustat, an older oral drug, can partially cross the barrier, but a small type 3 trial found no clinically meaningful neurological benefit, the review says.
Venglustat takes another route. The FDA describes it as a glucosylceramide synthase inhibitor that reduces the buildup of harmful fatty substances, called glucosphingolipids, throughout the body and in the brain. Its ability to cross the blood-brain barrier, the agency says, lets it reach the source of the accumulation.
The trial numbers and the safety warnings
Sanofi’s approval announcement names the study LEAP2MONO and says the company compared the drug with the enzyme therapy imiglucerase. The primary endpoint combined a global test of motor function (mSARA) and cognitive function (RBANS), and Infilbray showed statistically significant superiority, with a p-value of 0.0137. In its May 28 priority-review release, Sanofi said the drug met both primary endpoints and three of four key secondary endpoints, and that the study is ongoing; the same release describes the disease as one in which fatty molecules accumulate in the spleen, liver, bone marrow and lungs and, in the central nervous system, drive neuroinflammation. Among the 21 patients on Infilbray and 22 on imiglucerase, diarrhea occurred in 14% versus 0%, splenomegaly in 14% versus 0%, and nausea in 14% versus 5%.
The warnings are serious. The FDA says serious psychiatric risks, including suicidal ideation and behavior, have been reported, and that the most frequently reported effects were gastrointestinal symptoms and adverse effects on mood. Animal studies identified potential clouding of vision in younger patients and adverse effects on fetal development when the drug is taken during pregnancy. Sanofi lists suicidal ideation and behavior, lens opacification in children and embryofetal toxicity as its warnings and precautions.
What families and clinicians say, and what is unknown
Aviva Rosenberg, co-founder and chief executive of the Gaucher Community Alliance, called the approval “a long-awaited advancement for those experiencing devastating neurological symptoms,” in Sanofi’s release. Pramod Mistry, who directs the Yale Lysosomal Disease Center and Gaucher Disease Treatment Center, described it as “a major milestone for patients, families, and the global Type 3 Gaucher disease community.”
Open questions remain. Sanofi’s release gives no U.S. launch date and no price. The drug is under regulatory review in the European Union and Japan, and the company plans more global submissions in 2026 and 2027. The pivotal evidence rests on 43 people, studied for 52 weeks, who were already stable on enzyme therapy, so the published materials say little about patients who have not had enzyme therapy.
This article was produced with the assistance of AI and reviewed by Morning Overview editors prior to publication.
More from Morning Overview
- A $1 billion gas plant planned for Superior, Wisconsin, has been abandoned
- Shaq spent $1.3 million on three Rolls-Royce Phantoms to prove a point to a salesman
- The Justice Department asked courts to undo approvals for three offshore wind farms, one already making power
- Over 20 trillion gallons of rain fell on the Four Corners states and Nevada in two weeks